In selecting the right patients for adjuvant systemic chemotherapy (aCT), most guidelines roughly distinguish three groups, i.e. estrogen (ER +)- and or progesterone (PR +)-driven HER2-negative IBC, HER2-driven (ER-/PR-, HER2 +) IBC and triple negative IBC (TNBC) (ER-, PR-, HER2-) [4, 6, 7, 10–12]. Here, ERBB2 is linked to inflammatory breast carcinoma.